Roche lung cancer drug extends survival by nearly six months in late-stage trial

source: news (news:seeking-alpha)published 2026-10-25 22:02ingested 2026-10-26 02:57

retained text

Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

Roche lung cancer drug extends survival by nearly six months in late-stage trial

Oct 25, 2026, 6:02 PM ETRoche Holding AG (RHHBY) Stock, RHHBF Stock, RHHVF StockAMGN, BMY, MRKBy: Rob Williams, SA News Editor

Roche Holding (RHHBF) (RHHBY) (RHHVF) said its experimental lung cancer drug divarasib extended patient survival by nearly six months compared with competing treatments in a late-stage clinical trial, potentially strengthening the Swiss pharmaceutical company's oncology portfolio.

The treatment outperformed Amgen's (

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You

document fetched 2026-10-26 02:57 · canonical https://seekingalpha.com/news/4657007-roche-lung-cancer-drug-extends-survival-by-nearly-six-months-in-late-stage-trial?feed_item_type=news